Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.70 |
| ▸ | CNR1 | P21554 | 5/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497046 | 0.99 | CNR2 (0.71) | CNR2CNR1TDP1 | |
| SCHEMBL497220 | 0.99 | CNR2 (0.71) | CNR2CNR1TDP1 | |
| SCHEMBL497103 | 0.92 | CNR2 (0.71) | CNR2CNR1TDP1 | |
| SCHEMBL496518 | 0.91 | CNR2 (0.72) | CNR2CNR1TDP1 | |
| SCHEMBL495971 | 0.90 | CNR2 (0.74) | CNR2CNR1TDP1 | |
| SCHEMBL496864 | 0.90 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL496561 | 0.90 | CNR2 (0.74) | CNR2CNR1TDP1 | |
| SCHEMBL496427 | 0.89 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL496171 | 0.89 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL495960 | 0.86 | CNR2 (0.74) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012022865-A3 | DEVICE FOR ASSEMBLING A VEHICLE ENGINE AUTOMATIC STOP-START ASSEMBLY ON THE BODY SHELL STRUCTURE OF THE VEHICLE AND ASSOCIATED METHOD OF ASSEMBLY | Peugeot Citroën Automobiles SA (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-1602658-B1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-12-07 | — | — | EP | claimed |
| US-7485730-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2009-02-03 | — | — | US | claimed |
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2005-12-22 | — | — | US | claimed |
| EP-1602658-A1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | Neuroscienze Oharmaness S.c.a.r.l. (IT) | 2005-12-07 | — | — | EP | claimed |
| WO-2012022865-A3 | DEVICE FOR ASSEMBLING A VEHICLE ENGINE AUTOMATIC STOP-START ASSEMBLY ON THE BODY SHELL STRUCTURE OF THE VEHICLE AND ASSOCIATED METHOD OF ASSEMBLY | Peugeot Citroën Automobiles SA (FR) | 2012-05-10 | — | — | WO | disclosed |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENCZE PHARMANESS S.C. A R.L. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-8106218-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2012-01-31 | — | — | US | disclosed |
| EP-1602658-B1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-12-07 | — | — | EP | disclosed |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CENERX BIOPHARMA (US) | 2009-03-26 | — | — | US | disclosed |
| US-7485730-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2005-12-22 | — | — | US | disclosed |
| EP-1602658-A1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | Neuroscienze Oharmaness S.c.a.r.l. (IT) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | CNR2, CNR1, GPR55 | CNR2 1/4885CNR1 2/4885TDP1 4833/4885 |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885TDP1 4802/4885 |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885TDP1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.